Regulus Therapeutics (STU:7RG0) ROCE % : -42.58% (As of Jun. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Regulus Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Regulus Therapeutics's annualized ROCE % for the quarter that ended in Jun. 2024 was -42.58%.

Regulus Therapeutics ROCE % Historical Data

The historical data trend for Regulus Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regulus Therapeutics ROCE % Chart

Regulus Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-151.46

-57.47

-61.68

-58.59

-100.91

Regulus Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
ROCE %	Get a 7-Day Free Trial															-85.62	-95.51	-121.36	-51.37	-42.58

Regulus Therapeutics ROCE % Calculation

Regulus Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-26.989	/	( ( (44.1 - 11.004)	+	(28.198 - 7.802) )	/ 2 )
	=	-26.989	/	( (33.096	+	20.396)	/ 2 )
	=	-26.989	/	26.746
	=	-100.91 %

Regulus Therapeutics's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Mar. 2024 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Mar. 2024 )		(Q: Jun. 2024 )
	=	-40.792	/	( ( (105.007 - 5.227)	+	(96.727 - 4.889) )	/ 2 )
	=	-40.792	/	( ( 99.78	+	91.838 )	/ 2 )
	=	-40.792	/	95.809
	=	-42.58 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2024) EBIT data.

Regulus Therapeutics (STU:7RG0) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Regulus Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Regulus Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Regulus Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regulus Therapeutics Inc (STU:7RG0) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

RGLS:USA

Address

4224 Campus Point Court, Suite 210, San Diego, CA, USA, 92121

Website

https://www.regulusrx.com

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

Regulus Therapeutics Headlines

No Headlines